Abstract 14568: Three-year Restenosis Rate and Its Predictors After Endovascular Therapy for Leriche Syndrome
Introduction: Although current guidelines recommend surgical revascularization as the first-line therapy for chronic total occlusion of the abdominal aorta (Leriche syndrome), endovascular therapy (EVT) has been increasingly utilized due to the development of new technologies as well as techniques. EVT has demonstrated durable midterm outcomes in this field. Nonetheless, little is known about their long-term outcomes and predictors of restenosis.
Methods: We retrospectively analyzed a multicenter database of 64 consecutive patients (age, 73 ± 9 years; 64% male; 22% CLI) undergoing EVT for chronic total occlusion of the abdominal aorta between September 2005 and March 2016. The outcome measures were primary and secondary patency following EVT calculated by Kaplan-Meier method. Independent predictors associated with the restenosis were assessed by Cox proportional hazard regression model.
Results: Technical success was achieved in 61 patients (95%). Totally 214 stents (192 self-expandable stent, 22 balloon-expandable stent) were implanted. During the follow-up of 33 ± 28 months, 11 patients experienced restenosis. The primary patency rate was 88%, 82%, and 70% at 1, 2, and 3 years, respectively. The secondary patency rate was 98%, 95%, and 87% at 1, 2, and 3 years, respectively. In Cox regression analysis, E-luminexx stent use (in 29 patients, 48%) was associated with the restenosis [HR, 4.41; P = 0.038]. (Figure)
Conclusions: In this retrospective study, EVT for chronic total occlusion of the abdominal aorta demonstrated favorable 3-year outcomes. E-luminexx stent implantation was associated with the restenosis in this population.
Author Disclosures: K. Nanto: None. O. Iida: None. M. Fujihara: None. Y. Tomoi: None. Y. Soga: None. M. Fujita: None. M. Masuda: None. S. Okamoto: None. T. Ishihara: None. T. Kanda: None. T. Tsujimura: None. A. Sunaga: None. K. Yanaka: None. S. Okuno: None. Y. Matsuda: None. T. Ohashi: None. M. Uematsu: None.
- © 2016 by American Heart Association, Inc.